Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: mcbio who wrote (207)	11/16/2012 12:28:20 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 321

Thanks! >> ARRY expects that there will be combo data for the 8, 9, or 10 combo trials that NVS is running with MEK162 at ASCO 2013 << Can't wait, exactly what I was hoping for! Not certain that I can come up with even 8 combo trials, but they've used the figure ten previously. Perhaps a LEE011 trial is already running, etc.? Adding to your notes, 614 is currently dosing at about MTD, above levels achieved with the old formulation. Bioavailability is 2-3X, which should still leave a high pill burden? 12 pills at old form'n, and they've achieved higher levels in vivo... so say 24/3 = 8? Still don't get 520. To me, it's a project straight out of 1985. Why spend money on yet another molecule that kills tumor slightly faster than patient? Must be somebody's baby. I understand that everyone's mileage will vary. :-) Thanks again. Rick